Breaking News
April 19, 2019 - Key research takeaways from ECCMID 2019
April 19, 2019 - AI Can Identify Model of Cardiac Rhythm Device From Chest X-Ray
April 19, 2019 - New way to combat childhood anxiety: treat the parents
April 19, 2019 - Women getting C-sections best judge of own pain medication needs | News Center
April 19, 2019 - Immune responses that prevent fungal infections may eliminate Trichinella spiralis
April 19, 2019 - Exercising in the morning, rather than at night, may yield better results, shows study
April 19, 2019 - Why eating ‘right’ could cause you to stray from your diet
April 19, 2019 - Health Tip: Antidepressant Precautions – Drugs.com MedNews
April 19, 2019 - Bigger portions lead to preschoolers eating more over time
April 19, 2019 - Specific strains of Staphylococcus aureus linked to wounds that do not heal
April 19, 2019 - Revolutionary discovery paves new way for treatment of necrotizing enterocolitis
April 19, 2019 - Drug that treats high blood pressure shows promise against neurodegenerative diseases
April 19, 2019 - More care is needed for patients after kidney transplantations, reports research
April 19, 2019 - Virtual reality offers benefits for Parkinson’s disease patients
April 19, 2019 - Liver Illness Strikes Latino Children Like A ‘Silent Tsunami’
April 19, 2019 - Disruptive behaviors in autistic children linked to reduced brain connectivity
April 19, 2019 - New insights into how vitamin D affects immune system
April 19, 2019 - Pfizer Announces Presentation of Data from a Phase 2 Study of its 20-Valent Pneumococcal Conjugate Vaccine Candidate Being Investigated for the Prevention of Invasive Disease and Pneumonia in Adults Aged 18 Years and Older
April 19, 2019 - Exercise can improve non-motor symptoms of Parkinson’s disease
April 19, 2019 - KZFPs play a key role in the regulation of human genome
April 19, 2019 - Extracts of ginkgo seeds show antibacterial activity on pathogens that cause skin infections
April 19, 2019 - Groundbreaking experiment in pigs challenges the notion about brain damage
April 19, 2019 - Improving the quality of digital pathology imaging
April 19, 2019 - Scientists get closer to injecting artificial lymph nodes into people to fight disease
April 19, 2019 - Exercises and swimming goggles may reduce adverse effects on eye during long spaceflights
April 19, 2019 - Review suggests a reciprocal relationship between obesity and self-control
April 19, 2019 - Study identifies how enterococci bacteria cause antibiotic-resistant bloodstream infections
April 19, 2019 - Triple negative breast cancer develop resistance to chemotherapy by turning on molecular pathway
April 19, 2019 - Researchers identify key clues to brain and pancreas development
April 19, 2019 - Metformin May Cut Risk for Prematurity, Miscarriage in PCOS
April 19, 2019 - Obese mouse mothers trigger heart problems in offspring
April 19, 2019 - Research sheds light on how leukemia cells become resistant to drugs
April 19, 2019 - Health Tip: Stopping Nosebleeds – Drugs.com MedNews
April 19, 2019 - Pediatric endocrinologist gives iconic ‘Mona Lisa’ a second medical opinion
April 19, 2019 - Tapping patients’ wisdom for C-section pain management
April 18, 2019 - Why have autism rates ‘exploded’ in New Jersey?
April 18, 2019 - Microbiome science may help doctors to improve treatment for children with IBS
April 18, 2019 - New gene therapy cures babies with fatal ‘Bubble Boy’ disease
April 18, 2019 - No female mice? Scientists may still approve NIH grant
April 18, 2019 - What needs to be said about mental health in medicine
April 18, 2019 - Hickenlooper Expanded Medicaid, Created State-Run Marketplace To Insure Nearly All Coloradans
April 18, 2019 - Cancer cells grown in tumor-mimicking environment can help predict the effect of experimental drugs
April 18, 2019 - Albireo Announces FDA Clearance of IND to Commence Phase 2 Trial of Elobixibat for the Treatment of NAFLD/NASH
April 18, 2019 - Adhesive gel bonds to eye surface, could repair injuries without surgery
April 18, 2019 - The future of genomics: A podcast featuring Stanford geneticists
April 18, 2019 - As Syphilis Invades Rural America, A Fraying Health Safety Net Is Failing To Stop It
April 18, 2019 - APOE gene impacts sleep depending on gender and severity of Alzheimer’s
April 18, 2019 - PCORI’s newly approved awards focus on cancer pain and opioid use disorders
April 18, 2019 - New tool provides a standard way to measure effects of caring for survivors of TBI
April 18, 2019 - Smartphone use risks eye examination misdiagnosis
April 18, 2019 - How drug-resistant bugs grow in CF patients’ lungs
April 18, 2019 - Gordana Vunjak-Novakovic Elected to American Academy of Arts & Sciences
April 18, 2019 - Podcast: KHN’s ‘What The Health?’ You Have Questions, We Have Answers
April 18, 2019 - Diabetic drug shows potential to be repurposed as heart disease treatment for non-diabetic patients
April 18, 2019 - New estimation method assesses natural variations in sex ratio at birth
April 18, 2019 - UTA scientist receives $1.17 million grant for cancer research
April 18, 2019 - Coagulation factor VIIa prevents bleeds in hemophilia animal models
April 18, 2019 - Researchers identify risk factors for severe infection after knee replacement
April 18, 2019 - Mass drug administration can offer community-level protection against malaria
April 18, 2019 - FDA’s added sugar label could have substantial health and cost-saving benefits
April 18, 2019 - Researchers identify cause of inherited metabolic disorder
April 18, 2019 - Single strip of white paint not sufficient to protect people who ride bikes
April 18, 2019 - Partner status influences link between sexual problems and self-efficacy in breast cancer survivors
April 18, 2019 - Colorectal Neoplasia Risk Up for Hodgkin Lymphoma Survivors
April 18, 2019 - Rigid spine muscular dystrophy – Genetics Home Reference
April 18, 2019 - Simple bile acid blood test could tell risk of stillbirth
April 18, 2019 - Center for Experimental Therapeutics aims to enable all steps of drug development | News Center
April 18, 2019 - Falling for telephone scams could be an early sign of dementia
April 18, 2019 - Researchers annotate key neuronal proteins in lamprey genome
April 18, 2019 - Study uncovers new biomarker for personalized cancer treatments
April 18, 2019 - Scientists enter research collaboration to find a cure for cancer
April 18, 2019 - Study to compare benefits of tai chi and mindfulness meditation on MS symptoms
April 18, 2019 - Gestational diabetes during pregnancy may increase risk of type 1 diabetes in children
April 18, 2019 - Maternal age has no effect on IVF success, conclude researchers
April 18, 2019 - Is a New Remedy for Body Odor on the Horizon?
April 18, 2019 - Orthostatic hypotension – Genetics Home Reference
April 18, 2019 - Healing the heartbreak of stillbirth and newborn death
April 18, 2019 - New study calls healthiness of eggs into question
April 18, 2019 - Conference to highlight advances in human immune monitoring, bioinformatics | News Center
April 18, 2019 - Bacteria use viruses for self-recognition, study reveals
From Our Bench to Yours: Antibody Advice from Proteintech

From Our Bench to Yours: Antibody Advice from Proteintech

image_pdfDownload PDFimage_print

Please can you introduce yourself and the role you carry out at Proteintech?

I am a technical scientist and product manager at Proteintech. My role involves helping our customers optimize their research results and address any concerns through technical support by sharing our experimental tips and engaging scientists via our blog channel. I also write articles on upcoming techniques and novel applications of our products.

molekuul_bemolekuul_be | Shutterstock

I also run technical masterclasses for young scientists, along with training webinars. Our next masterclass is on January 29, 2019, at the University of Newcastle, where we’ll be teaching students to master western blotting and immunofluorescence, including tips on how to optimize your protocols and overcome common experimental obstacles.

What makes an antibody good or bad? How can a scientist tell if a seller is trustworthy or not?

When generating an antibody, you can either immunize with a whole protein or a small synthetic peptide fragment that you are interested in detecting. At Proteintech, we take a whole protein approach to the antibodies we offer as this provides several benefits for the researcher.

Ninety-five percent of Proteintech antibodies are raised against whole proteins, letting the immune system choose the best epitopes for generating antibodies. This approach provides superior antibody binding to the native target protein at multiple epitopes compared to peptide immunogens, and secondly, the specificity and sensitivity of the assay are improved.

The final advantage is that the antibody can be used in more applications. For example, many assays can be used to study a single antigen, but each assay may require a slightly different antibody depending on the epitope.

Some regions of the protein may be better for one application than another, so the availability of the whole protein yields antibodies that can work for multiple applications. This is more likely to occur with a whole protein approach compared to a single fragment. Since the immune system can generate antibodies against any region of the whole protein, there is also a high chance of reactivity across species due to conservation.

To summarize, the three main advantages of whole-protein antibodies are:

  • wider applicability,
  • higher binding sensitivity and affinity,
  • superior recognition of native, intact proteins.

Another sign of reliability is whether the company selling the antibody is a manufacturer and distributor, or just a distributor (re-seller). This is important because if you have an issue or query about an antibody, you need to be able to obtain RAW validation data. If that data has not been collected in-house, it will take longer for the company to collate it, which can potentially delay your experiments.

Proteintech – a direct manufacturer (Credit: Proteintech)

At Proteintech, all of our data is freely available online and our antibodies have been cited in hundreds of publications. When an obscure application is queried, we can provide the validation data to support or refute the experiment and do so within 24 hours. We are proud to show realistic data that hasn’t been “cleaned up” to look perfect but will give you an idea of how the western blot, for example, will look time and time again. I think that’s a particularly good sign of trustworthiness.

Why is reproducibility important and how do Proteintech ensure this for each of their antibodies?

Every scientist wants to get the same results every time when working with the same antibody. As I mentioned, we are the only manufacturer, so we can provide instant support for scientists who are troubleshooting their methods.

Another sign of quality is the purification method used. We use affinity chromatography, which makes use of the binding strength of a protein for its ligand. Another popular method is protein A/G purification, which uses the recombinant fusion protein A/G from E. coli. Protein A/G purification will yield all IgGs in the serum, not just the desired antibodies. Affinity chromatography selects for just the ones with the highest affinity toward the target.

We also validate our antibodies through knockout and knockdown (KO/KD) studies. Proteintech was the first company to implement siRNA knockdown validation experiments, the gold standard for testing antibody specificity. The validation process involves using small interfering RNA to knock down gene expression in an antibody product – assessing whether the signal subsides with the expression of the target gene.

This is critical for ensuring consistent and reliable results and is far superior to validation using positive controls only. In 2016 we were awarded the CiteAb prize for the ‘most exciting antibody validation initiative’.

The following year, Proteintech was the company with the largest percentage increase in citations based on data gathered between January 2017 and December 2017 (“Highly commended antibody supplier’ in CiteAb 2018 awards”).

We also compare all of our antibodies lot-to-lot, which helps us to detect changes in performance between batches. If a new lot fails to perform either as well as or better than the previous one, it is unsellable, and we begin production on another lot.

Is it possible to use the same antibody for multiple applications? How are Proteintech working to improve this?

As scientists, we would love to have one antibody for all applications, but unfortunately, this is a challenge. Simply put, the biochemistry of each assay is markedly different. For example, in Westerns, the protein is denatured, but in immunohistochemistry (IHC), the protein is in native form in its cellular context.

However, one thing we are trying to do as a company is to provide antibody specific protocols, that a scientist can find easily on our website. This might mean a slightly longer incubation time, an antigen retrieval step (in the case of IHC or IF), or a different blocking step, etc.

You recently purchased Humanzyme, a company that produces recombinant human proteins. Why did you feel this was a necessary step for Proteintech and what advantages do recombinant proteins provide?

For over 15 years, we have been trying to create the best antibodies by bucking the trend of using peptides and instead using whole-protein immunogens. Humanzyme has been making the best proteins by forgoing bacteria and hamsters and using human cells (HEK293) to make human proteins with native glycosylation, multimerization, and processing. You could say that we go together like an antibody and a protein!

For human applications and research, a human cell expression system is ideal. I find this fascinating: Humanzyme products can be used to study native post-translational modification and protein folding in regenerative medicine.

Recombinant proteins provide many advantages over proteins derived from other organisms. The first major benefit is potency; recombinant cells produce proteins with a higher potency than E. coli-derived proteins, for example.

In addition, recombinant human proteins are glycosylated by protein chaperones, which are only available in eukaryotic cells. Insect and Chinese hamster ovary (CHO) cells cannot do this, and the result is a product that is less representative of the native protein and doesn’t work with many assays.

Comparison of proteins produced using different expression systems. Colored circles denote level of similarity to human proteins. (Credit: Proteintech)

What does the future look like for Proteintech?

For the next few years, we’ll be focusing on expanding our recombinant human protein products while also looking into new applications for our current products.

We recently launched a product line called CoraLite, which is a series of fluorescent-dye conjugated antibodies that can be used in immunofluorescence and flow cytometry. CoraLite allows scientists to produce beautiful IF images from direct labeling.

Coralite fluorescent-dye conjugated Proteintech antibodies (Credit: Proteintech)

Our hope is for Humanzyme to grow very quickly, especially when the products are approved for use in Good Manufacturing Practice (GMP) labs, which should be happening the next year. This will open the door for Proteintech to start working with more pharmaceutical and biomedical companies. Overall, the future looks bright!

Where can readers find more information?

For more information, please visit the Proteintech website.

About Karolina Szczesna

Dr. Karolina Szczesna is an experienced product and project manager with more than 7 years’ experience in coordinating multiple international projects, including project plans and management, testing novel screening methods, launching new products, and developing relationships between researchers and commercial partners.

Her scientific focus is related mostly to the Central Nervous System and Oncological Disease Models (e.g., cancer stem cells, cancer epigenetics, and studies related to rare neurodevelopment diseases). Karolina’s scientific achievements are reflected in more than 10 PubMed Publications.

At Proteintech she is a multilingual Product Manager and Technical Support Specialist, being responsible for the coordination of international collaborations and market branding worldwide, including speaking about science novelty and technology at top European universities.

About Proteintech

Proteintech is an antibody and human protein manufacturer selling directly to scientists and only selling its own products in order to maintain the highest level of quality control, leading to superior reproducibility and lot consistency. With over 2/3 of the human genome completed, we have a catalog of over 12,000 antibodies against 12,000 targets covering a wide spectrum of research areas.

We have been cited in tens of thousands of publications and provide in-house validation of our antibodies in WB, IHC, IF, FC, IP, and CHIP, in addition to performing siRNA knockdown validation of our antibodies. Additionally, we provide human cell-expressed proteins that have authentic glycosylation and folding, yielding higher activity and stability over proteins from other hosts.

Tagged with:

About author

Related Articles